7 research outputs found
T cell homing to nasopharyngeal carcinoma
Undifferentiated nasopharyngeal carcinoma (NPC) is a very good candidate disease for treatment with adoptive T cell transfer. Uniformly Epstein-Barr virus (EBV)+, these tumours
reportedly have functional antigen processing and presentation machinery and express viral proteins that contain known cytolytic T cell target epitopes. This raises the possibility that boosting relevant EBV-specific T cell immunity in NPC patients might defeat the tumour. The
persistent nature of EBV infection may also encourage the long-term survival of therapeutically administered virus-specific cells. However, efficient delivery of tumour-specific T cells from the circulation to solid tumour tissue is a clear requirement for effective cellular therapy, yet the mechanisms by which T cells gain entry to NPC tumours have not yet been determined. The malignant cells of NPC are usually associated with a substantial lymphoid infiltrate mainly consisting of T cells. Using unmanipulated diagnostic biopsy samples, we have characterised chemokine receptor expression (CR) on tumour-infiltrating T cells, and established whether specific chemokine ligands are detectable at the NPC tumour site. We found that functional CXCR6 and CCR5 were expressed on tumour infiltrating T cells, consistent with the presence of specific ligands for these receptors at the tumour site. Furthermore, our data suggests that effector and regulatory cells may use shared homing mechanisms to gain entry to NPC tumours
CXCR6 and CCR5 localize T lymphocyte subsets in nasopharyngeal carcinoma
The substantial T lymphocyte infiltrate found in cases
of nasopharyngeal carcinoma (NPC) has been implicated
in the promotion of both tumor growth and
immune escape. Conversely, because malignant NPC
cells harbor the Epstein-Barr virus, this tumor is a
candidate for virus-specific T cell-based therapies.
Preventing the accumulation of tumor-promoting T
cells or enhancing the recruitment of tumor-specific
cytotoxic T cells offers therapeutic potential. However,
the mechanisms involved in T cell recruitment
to this tumor are poorly understood. Comparing
memory T cell subsets that have naturally infiltrated
NPC tissue with their counterparts from matched
blood revealed enrichment of CD8�, CD4�, and regulatory
T cells expressing the chemokine receptor
CXCR6 in tumor tissue. CD8� and (nonregulatory)
CD4� T cells also were more frequently CCR5� in
tumor than in blood. Ex vivo studies demonstrated
that both receptors were functional. CXCL16 and
CCL4, unique chemokine ligands for CXCR6 and
CCR5, respectively, were expressed by the malignant
cells in tumor tissue from the majority of NPC cases,
as was another CCR5 ligand, CCL5. The strongest expression
of CXCL16 was found on tumor-infiltrating
cells. CCL4 was detected on the tumor vasculature in a
majority of cases. These findings suggest that CXCR6
and CCR5 play important roles in T cell recruitment
and/or retention in NPC and have implications for the
pathogenesis and treatment of this tumo